Last updated on October 2018

Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis

Brief description of study

The purpose of this study is to compare the safety and efficacy of secukinumab monotherapy and adalimumab monotherapy in patients with active psoriatic arthritis who are nave to biologic therapy and are intolerant or having inadequate response to conventional DMARDs

Clinical Study Identifier: NCT02745080

Contact Investigators or Research Sites near you

Start Over

Novartis Pharmaceuticals

Novartis Investigative Site
Gyor, Hungary
  Connect »